Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + prednisone with metronomic cyclophosphamide + celecoxib in hormone-refractory prostate cancer
2006-004478-29Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Sep 2012
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, prednisone, cyclophosphamide and celecoxib in prostate cancer (PCa), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Progression-free survival (PFS). Started Sep 2012; status: active.
02
Drugs
docetaxelprednisonecyclophosphamidecelecoxib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-004478-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004478-29.